Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2018
At a glance
- Drugs Nivolumab (Primary) ; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Jan 2018 Status changed from not yet recruiting to recruiting.
- 19 Dec 2017 Planned End Date changed from 1 Jul 2023 to 1 Jul 2022.
- 19 Dec 2017 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2021.